FDA warns of reduced Redseweefficia

16 (Xinhua) — The U.S. Food and Drug Administration (FDA) warned Monday that the combination of the antimalarial drug hydroxychloroquine and the antiviral drug remdesivir could weaken the latter’s effectiveness if the new coronary pneumonia drug is combined. “It is not recommended to use Redsivir and chloroquine phosphate or hydroxychloroquine sulfate in combination, as this may lead to a decrease in Redsivir’s antiviral activity,” the FDA said. “

FDA warns of reduced Redseweefficia

In a report released late Monday, U.S. time, the agency said a recently completed non-clinical study had identified potential drug interactions, and that “it is not clear whether this decrease in activity will occur in the clinical environment, but it is continuing to evaluate all data related to Redsewe.” “

Redsewe, produced by GilledEr Sciences of the United States, obtained an FDA emergency use authorization in May to treat hospital patients with new coronary pneumonia. Hydroxychloroquine was previously approved for the treatment of patients with new coronary pneumonia in emergency situations, but the designation was withdrawn early Monday after the FDA found it unlikely to be effective.

News of this potential drug interaction may further dampen hopes that hydroxychloroquine could help ward off the new coronavirus.